171 related articles for article (PubMed ID: 9052754)
21. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.
Blommaert FA; Floot BG; van Dijk-Knijnenburg HC; Berends F; Baan RA; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Chem Biol Interact; 1998 Jan; 108(3):209-25. PubMed ID: 9528691
[TBL] [Abstract][Full Text] [Related]
22. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
23. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
Shellard SA; Fichtinger-Schepman AM; Lazo JS; Hill BT
Anticancer Drugs; 1993 Aug; 4(4):491-500. PubMed ID: 8400352
[TBL] [Abstract][Full Text] [Related]
24. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells.
Brandt TY; Ali-Osman F
Toxicol Appl Pharmacol; 1997 Mar; 143(1):22-9. PubMed ID: 9073588
[TBL] [Abstract][Full Text] [Related]
25. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
26. Nucleotide excision repair phenotype of human acute myeloid leukemia cell lines at various stages of differentiation.
Hsu PH; Hanawalt PC; Nouspikel T
Mutat Res; 2007 Jan; 614(1-2):3-15. PubMed ID: 16890248
[TBL] [Abstract][Full Text] [Related]
27. Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity.
Awuah SG; Riddell IA; Lippard SJ
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):950-955. PubMed ID: 28096358
[TBL] [Abstract][Full Text] [Related]
28. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
29. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
30. Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies.
Parris CN; Walker MC; Masters JR; Arlett CF
Cancer Res; 1990 Dec; 50(23):7513-8. PubMed ID: 2253200
[TBL] [Abstract][Full Text] [Related]
31. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
32. Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin.
Dempke W; Voigt W; Grothey A; Schmoll HJ
Anticancer Drugs; 1999 Jul; 10(6):545-9. PubMed ID: 10885902
[TBL] [Abstract][Full Text] [Related]
33. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
Maynard KR; Hosking LK; Hill BT
Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540
[TBL] [Abstract][Full Text] [Related]
34. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
35. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
36. Sporadic testicular germ cell cancers do not exhibit specific alteration in CAG/CTG repeats containing genes expressed in human testis.
Ono Y; Rajpert De-Meyts E; Guellaën G; Bulle F
Oncogene; 2001 Sep; 20(39):5548-53. PubMed ID: 11571654
[TBL] [Abstract][Full Text] [Related]
37. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines.
Wilson C; Yang J; Strefford JC; Summersgill B; Young BD; Shipley J; Oliver T; Lu YJ
Genes Chromosomes Cancer; 2005 Jun; 43(2):211-6. PubMed ID: 15761863
[TBL] [Abstract][Full Text] [Related]
39. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro.
Dempke WC; Shellard SA; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1991 Mar; 12(3):525-8. PubMed ID: 1901253
[TBL] [Abstract][Full Text] [Related]
40. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
